Abstract 458P
Background
Analysis of ctDNA in operable NSCLC for the identification of patients at high risk of relapse could allow tailoring of adjuvant therapy with EGFR tyrosine kinase inhibitors (TKIs). We assessed whether tracking of EGFR mutations in plasma circulating tumor DNA (ctDNA) predicts relapse in completely resected EGFR-mutant NSCLC.
Methods
A prospective cohort of 45 EGFR-mutant stage I-IIIB NSCLC patients, all of whom underwent complete resection of their tumors, had plasma samples for ctDNA analysis taken post-surgery and in follow-up. Cobas EGFR Mutation Test (cobas) was used for tissue genotyping of the baseline tumor biopsy or surgical specimens, and droplet digital PCR (ddPCR) was performed to track the identified EGFR mutations in ctDNA.
Results
We identified EGFR exon 19 deletions (n = 23), L858R (n = 18), and L861Q (n = 4) mutations by cobas in pre-surgical tissue biopsies and/or surgical specimens, and used ddPCR assays for each EGFR mutation to measure ctDNA after surgery. Detection of ctDNA after complete tumor resection in 11 of 45 (24%) patients significantly predicted clinical relapse (hazard ratio [HR] 7.0, 95% confidence interval [CI] 2.13 to 22.68; log-rank p = 0.001). Multivariable analysis demonstrated that detection of ctDNA remained a significant predictor of clinical relapse after adjusting for clinical factors (HR 6.16, 95% CI 1.80 to 21.06; p = 0.004). Notably, ctDNA-based molecular relapse demonstrated a lead time of up to 8.1 months over clinical relapse.
Conclusions
Tracking of EGFR mutations in cfDNA following surgical treatment can identify NSCLC patients at high risk of relapse. Whether ctDNA monitoring could allow tailoring of adjuvant therapy with EGFR tyrosine kinase inhibitors will have to be determined in future clinical trials.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
AstraZeneca.
Disclosure
M. Filipits: Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): AstraZeneca; Honoraria (self), Advisory / Consultancy: Boehringer Ingelheim. M.J. Hochmair: Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: Boehringer Ingelheim. A. Buder: Honoraria (self): AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
97P - The role of adjuvant chemotherapy according to the status of surgical margin in rectal cancer
Presenter: Jong Hoon Lee
Session: Poster display session
Resources:
Abstract
98P - Influence of DPYD*9, DPYD*6 and GSTP1 ile105val genetic polymorphisms on capecitabine and oxaliplatin (CAPOX) associated toxicities in colorectal cancer patients
Presenter: Ashok Varma
Session: Poster display session
Resources:
Abstract
99P - Patient-derived tumour model by new culture method leading to the precision medicine
Presenter: Norikatsu Miyoshi
Session: Poster display session
Resources:
Abstract
100P - Clinical impact and carcinogenic mechanism of NCAPG overexpression in colon cancer
Presenter: Kai-Yuan Lin
Session: Poster display session
Resources:
Abstract
101P - Combined cellular immunotherapy and chemotherapy improves clinical outcome and displays safety in the treatment of patients with colorectal cancer
Presenter: Chang Wang
Session: Poster display session
Resources:
Abstract
102P - Clinical features of anorectal cancer in patients with Crohn’s disease: Japanese single center study
Presenter: Kazuhiro Watanabe
Session: Poster display session
Resources:
Abstract
103P - Contrast-enhanced CT-based textural parameters as potential prognostic factors of survival for colorectal cancer patients receiving targeted therapy
Presenter: Yanfei Yang
Session: Poster display session
Resources:
Abstract
104P - Prognostic significance of tumour location to the oncologic outcome of colon cancer
Presenter: Sare Hosseini
Session: Poster display session
Resources:
Abstract
105P - Detection and clinical significance of circulating tumour cells in patients with rectal cancer
Presenter: Shuohui Dong
Session: Poster display session
Resources:
Abstract
106P - The risk of malignization incidence in patients with polyps and polyposis of the colon and rectum
Presenter: Yakov Ten
Session: Poster display session
Resources:
Abstract